Table 2.
Transplant Information.
| Variable | TME(+) | TME(−) | p |
|---|---|---|---|
| N (%) | 35 (47.3) | 39 (52.7) | |
| Conditioning | 0.103 | ||
| Chemotherapy only | 3 (8.5) | 3 (7.7) | |
| Serotherapy only | 6 (17.1) | 8 (20.5) | |
| Both | 4 (11.4) | 13 (33.3) | |
| Unconditioned | 22 (62.9) | 15 (38.5) | |
| Donor | 0.001 | ||
| Maternal | 29 (82.9) | 15 (38.5) | |
| Paternal | 1 (2.9) | 6 (15.4) | |
| Sibling | 4 (11.4) | 11 (28.2) | |
| Unrelated | 1 (2.9) | 7 (17.9) | |
| GVHD Prophylaxis | 0.016 | ||
| TCD | 30 (85.7) | 20 (51.3) | |
| CNI + MTX | 4 (11.4) | 14 (35.9) | |
| CNI Only | 1 (2.9) | 3 (7.7) | |
| CNI + MMF | 0 (0) | 2 (5.1) | |
| 10-Year Overall Survival | 76.0% | 83.7% | 0.43 |
| 10-Year Event-Free Survival | 73.8% | 65.6% | 0.30 |
TCD=T cell depleted; CNI=calcineurin inhibitor; MTX=methotrexate; MMF=mycophenolate mofetil.